Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Dynamic Effects of Glucocorticoid on Bone Mineral Density and Microarchitecture: Experiment with Rats

Effects of Methylprednisolone on Bone Mineral Density and Microarchitecture of Trabecular Bones in Rats with Administration Time and Assessed by Micro-Computed Tomography

[The effects of glucocorticoid on expression of cannabinoid-1 receptors in osteoclasts from tibial proximal metaphysis of rats].

Effects of Short-Term Glucocorticoid Administration on Bone Mineral Density, Biomechanics and Microstructure in Rats’ Femur

The Different Effects of Short-Term Application of Glucocorticoids in Cancellous and Cortical Bone in SD Rat

Effects of Glucocorticoids on Fracture Healing in Rats

A comparative study of the effects of glucocorticoid and ovariectomy on bone mass and metabolism in rats

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

Effect of glucocorticoid on bone mass in adult rats

Glucocorticoids disrupt longitudinal advance of cortical bone basic multicellular units in the rabbit distal tibia

Effects of mechanical stimuli on structure and organization of bone nanocomposites in rats with glucocorticoid-induced osteoporosis

Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats.

Effect of glucocorticoids on the changes of bone mineral density in patients with rheumatic autoimmune disease

Effect of glucocorticoids on osteoclast function in a mouse model of bone necrosis

Influence of Glucocorticoids on the Osteogenic Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells

Vitamin D Auto-/Paracrine System Is Involved in Modulation of Glucocorticoid-Induced Changes in Angiogenesis/Bone Remodeling Coupling

Anti-Inflammatory Effects of Low-Dose Glucocorticoids Compensate for Their Detrimental Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

Glucocorticoid: A Potential Role in Microgravity-Induced Bone Loss

Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study

OP0187 Transgenic Disruption of Glucocorticoid-Signaling in Mature Osteoblasts and Osteocytes Attenuates Structural Bone Damage in a Long-Term Murine K/bxn Serum-Induced Arthritis Model

Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis.